Aptevo reports frontline AML data for mipletamig, targets Phase 2 talks in early 2027Aug 14Quarterly updateAptevo Therapeutics
Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026Aug 12Quarterly updateKura Oncology, Inc.ziftomenib
Cullinan reports Q2 2026 results, outlines T cell engager trial timelinesAug 6Quarterly updateCullinan Therapeutics Inc.
Syndax reports 2Q26 revenue growth, details EGFR and menin inhibitor pipeline additionsAug 4Quarterly updaterevumenibSyndax Pharmaceuticals Inc
Moleculin reports 37% blinded CRc in venetoclax-failed AML patients from MIRACLE trialJul 31Clinical readoutMoleculin Biotech, Inc.venetoclax
AbbVie week: BOTOX oral pain results post; new CLL, myeloma, ABBV-859 trials filedJul 31Weekly roundup, 6 itemsABBV-859AbbVie
Cullinan Therapeutics registers Phase 1b trial of CLN-049 with azacitidine, venetoclax in AMLJul 23Trial updateazacitidineCLN-049
Sign inSign in